Электронный архив

Просмотр по автору "Rutland C.S."

Просмотр по автору "Rutland C.S."

Отсортировать по:Сортировать:Результаты поиска на странице:

  • Cell Culture Based in vitro Test Systems for Anticancer Drug Screening 
    Kitaeva K.V.; Rutland C.S.; Rizvanov A.A.; Solovyeva V.V. (2020)
    © Copyright © 2020 Kitaeva, Rutland, Rizvanov and Solovyeva. The development of new high-tech systems for screening anticancer drugs is one of the main problems of preclinical screening. Poor correlation between preclinical ...
  • Current trends in cancer immunotherapy 
    Filin I.Y.; Solovyeva V.V.; Kitaeva K.V.; Rutland C.S.; Rizvanov A.A. (2020)
    © 2020 by the authors. Licensee MDPI, Basel, Switzerland. The search for an effective drug to treat oncological diseases, which have become the main scourge of mankind, has generated a lot of methods for studying this ...
  • Epidemiology and Risk Factors of Osteosarcoma 
    Sadykova L.R.; Ntekim A.I.; Muyangwa-Semenova M.; Rutland C.S.; Jeyapalan J.N.; Blatt N.; Rizvanov A.A. (2020)
    © 2020, © 2020 Taylor & Francis Group, LLC. Osteosarcoma is a rare tumor diagnosed at any age; however younger age is a common risk factor. In addition, multiple factors are believed to contribute to higher rates of ...
  • Extracellular Vesicles: New Perspectives of Regenerative and Reproductive Veterinary Medicine 
    Zakirova E.Y.; Aimaletdinov A.M.; Malanyeva A.G.; Rutland C.S.; Rizvanov A.A. (2020)
    © Copyright © 2020 Zakirova, Aimaletdinov, Malanyeva, Rutland and Rizvanov. Extracellular vesicles are released by all cell types including stem cells. Stem cell-released extracellular vesicles have therapeutic effects ...
  • Immunohistochemical Characterisation of GLUT1, MMP3 and NRF2 in Osteosarcoma 
    Rutland C.S.; Cockcroft J.M.; Lothion-Roy J.; Harris A.E.; Jeyapalan J.N.; Simpson S.; Alibhai A.; Bailey C.; Ballard-Reisch A.C.; Rizvanov A.A.; Dunning M.D.; de Brot S.; Mongan N.P. (2021)
    Osteosarcoma (OSA) is an aggressive bone malignancy. Unlike many other malignancies, OSA outcomes have not improved in recent decades. One challenge to the development of better diagnostic and therapeutic methods for OSA ...
  • Molecular characterisation of canine osteosarcoma in high risk breeds 
    Simpson S.; Dunning M.; de Brot S.; Alibhai A.; Bailey C.; Woodcock C.L.; Mestas M.; Akhtar S.; Jeyapalan J.N.; Lothion-Roy J.; Emes R.D.; Allegrucci C.; Rizvanov A.A.; Mongan N.P.; Rutland C.S. (2020)
    © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Dogs develop osteosarcoma (OSA) and the disease process closely resembles that of human OSA. OSA has a poor prognosis in both species and disease-free intervals and ...
  • Mouse tumor models for advanced cancer immunotherapy 
    Chulpanova D.S.; Kitaeva K.V.; Rutland C.S.; Rizvanov A.A.; Solovyeva V.V. (2020)
    © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Recent advances in the development of new methods of cancer immunotherapy require the production of complex cancer animal models that reliably reflect the complexity ...
  • Proangiogenic effect of 2A-peptide based multicistronic recombinant constructs encoding VEGF and FGF2 growth factors 
    Gatina D.Z.; Garanina E.E.; Zhuravleva M.N.; Synbulatova G.E.; Mullakhmetova A.F.; Solovyeva V.V.; Kiyasov A.P.; Rutland C.S.; Rizvanov A.A.; Salafutdinov I.I. (2021)
    Coronary artery disease remains one of the primary healthcare problems due to the high cost of treatment, increased number of patients, poor clinical outcomes, and lack of effective therapy. Though pharmacological and ...
  • Recent Advances in Experimental Dendritic Cell Vaccines for Cancer 
    Filin I.Y.; Kitaeva K.V.; Rutland C.S.; Rizvanov A.A.; Solovyeva V.V. (2021)
    The development of immunotherapeutic methods for the treatment of oncological diseases have made it possible to improve the effectiveness of standard therapies. There was no breakthrough after first using of personalized ...

Поиск в электронном архиве

Просмотр

Моя учетная запись